115 related articles for article (PubMed ID: 18489515)
1. "Price management" and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.
Tordoff JM; Norris PT; Reith DM
Value Health; 2008 Dec; 11(7):1214-26. PubMed ID: 18489515
[TBL] [Abstract][Full Text] [Related]
2. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?
Tordoff JM; Norris PT; Reith DM
Value Health; 2005; 8(3):201-8. PubMed ID: 15877592
[TBL] [Abstract][Full Text] [Related]
3. Hospital drug therapy cost containment through a preferred medicines list and drug utilisation review system.
Pearce MJ; Begg EJ
N Z Med J; 1994 Mar; 107(974):101-4. PubMed ID: 8127505
[TBL] [Abstract][Full Text] [Related]
4. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
[TBL] [Abstract][Full Text] [Related]
5. Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience.
Braae R; McNee W; Moore D
Pharmacoeconomics; 1999 Dec; 16(6):649-60. PubMed ID: 10724792
[TBL] [Abstract][Full Text] [Related]
6. Effect of Japanese government policy on hospital pharmaceutical profit levels.
Oliver AJ; Ikegami N; Ikeda S
J Health Serv Res Policy; 1999 Jan; 4(1):27-32. PubMed ID: 10345563
[TBL] [Abstract][Full Text] [Related]
7. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Grocott R
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
[TBL] [Abstract][Full Text] [Related]
8. Measuring availability, affordability and management of essential medicines in public hospitals of Burkina Faso.
Saouadogo H
World Hosp Health Serv; 2011; 47(1):8-11. PubMed ID: 21675631
[TBL] [Abstract][Full Text] [Related]
9. Patient's medicines brought to hospital: an overlooked resource?
Ware GJ
N Z Med J; 1993 Oct; 106(966):453-4. PubMed ID: 8233178
[TBL] [Abstract][Full Text] [Related]
10. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
11. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
12. The influence of PHARMAC's National Hospital Pharmaceutical Strategy on Quality Use of Medicines activities in New Zealand hospitals.
Tordoff J; Norris P; Kennedy J; Reith D
N Z Med J; 2006 Aug; 119(1239):U2100. PubMed ID: 16912718
[TBL] [Abstract][Full Text] [Related]
13. Quality Use of Medicines activities in New Zealand hospitals from 2000 to 2002.
Tordoff JM; Norris P; Kennedy J; Reith D
N Z Med J; 2005 Jan; 118(1208):U1259. PubMed ID: 15682211
[TBL] [Abstract][Full Text] [Related]
14. [Supply prescription filling and out-of-pocket expenditures on medicines in public hospitals in Mexico in 2009].
Sesma-Vázquez S; Gómez-Dantés O; Wirtz VJ; Castro-Tinoco M
Salud Publica Mex; 2011; 53 Suppl 4():470-9. PubMed ID: 22282209
[TBL] [Abstract][Full Text] [Related]
15. Ontario and New Zealand Pharmaceuticals: Cost and Coverage.
Kelley LT; Tenbensel T; Johnson A
Healthc Policy; 2018 May; 13(4):23-34. PubMed ID: 30052187
[TBL] [Abstract][Full Text] [Related]
16. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
17. Projecting future drug expenditures--1993.
Santell JP
Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
[TBL] [Abstract][Full Text] [Related]
18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
19. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
20. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
